Abstract
Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Current Molecular Medicine
Title:Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response
Volume: 13 Issue: 4
Author(s): R.R. Dinglasan, J.S. Armistead, J.F. Nyland, X. Jiang and H.Q. Mao
Affiliation:
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Abstract: Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Export Options
About this article
Cite this article as:
Dinglasan R.R., Armistead J.S., Nyland J.F., Jiang X. and Mao H.Q., Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040002
DOI https://dx.doi.org/10.2174/1566524011313040002 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Immunomodulatory and Anti-Viral Activities of Pertussis Toxin and of Its Non-Toxic Derivatives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets Effect of Dietary Education on Cardiovascular Risk Factors in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Editorial (Hot Topic: Neuroprotection Against Stroke and CNS Injury: New Mechanisms, Targets, and Controversies)
CNS & Neurological Disorders - Drug Targets Intravenous Magnesium – Lidocaine - Ketorolac Cocktail for Postoperative Opioid Resistant Pain: A Case Series of Novel Rescue Therapy
Reviews on Recent Clinical Trials Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Current Pharmaceutical Design Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Complementary Therapies in Inflammatory Bowel Diseases
Current Drug Targets Viral Origins of Human Cancer
Current Medicinal Chemistry Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Editorial [Hot Topic: Non-Invasive Delivery of iRNAs, Proteins, Peptides, Cytokines and Nanoparticles (Guest Editor: Bingmei M. Fu)]
Current Pharmaceutical Biotechnology Current Status on Immunoprotection of Transplanted Islets: Focus on Islet Microencapsulation
Micro and Nanosystems Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters 1, 25(OH)<sub>2</sub>D<sub>3</sub> Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes
Current Medicinal Chemistry Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Histamine in Immune Regulation: Possible Roles in Autoimmune Demyelinating Disease of the Central Nervous System
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents